| Followers | 36 |
| Posts | 1127 |
| Boards Moderated | 0 |
| Alias Born | 08/23/2018 |
Sunday, November 11, 2018 6:40:15 PM
Maybe, maybe not. lots of players were unwilling to enter until full results were released...theyd rather buy $35 with great full results than $20 with only info pre nov 10th, as it will be highlllllyyy derisked and any smart investor knows it has triple digit upside.
the only reason i would speculate tomorrow not to fully gap as high as we expect is the markets will be slow for veterans day...that being said, if someone wants to acquire a large position, they will do it tomorrow regardless if they planned on going in to work. i know all the brokerage houses are at least half staffed on these days to make trading possible for clients.
any short will need to cover asap. and there are about 30million shares that will be short due to options if we rip through 30, which seems very likely. this press conference/proliferations of info/national attention DWARFS 9/24, and we jumped $10 that day and $13 that week. publicity literally could not be better, vascepa was featured in every city on TV and in papers, basically.
but youre right, market does really weird stuff all the time. still safe to have a week end theoretical price of >$45 or so i think. well have 150mil shares trade this week, no one will be manipulating $4billion notional...
the only reason i would speculate tomorrow not to fully gap as high as we expect is the markets will be slow for veterans day...that being said, if someone wants to acquire a large position, they will do it tomorrow regardless if they planned on going in to work. i know all the brokerage houses are at least half staffed on these days to make trading possible for clients.
any short will need to cover asap. and there are about 30million shares that will be short due to options if we rip through 30, which seems very likely. this press conference/proliferations of info/national attention DWARFS 9/24, and we jumped $10 that day and $13 that week. publicity literally could not be better, vascepa was featured in every city on TV and in papers, basically.
but youre right, market does really weird stuff all the time. still safe to have a week end theoretical price of >$45 or so i think. well have 150mil shares trade this week, no one will be manipulating $4billion notional...
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
